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dopam ine : A  M arke r o f  P sycho sis  and  F ina l 
Comm on  d rive r o f  Sch izoph ren ia  P sycho sis
Our attempt to understand schizophrenia in neurochemical terms began with the 
landmark studies of Carlsson and Lindqvist (1) in the 1960s. The results of these studies, 
based on the action of chlorpromazine, were strengthened by the binding studies car-
ried out in both Seeman’s (2) and Synder’s (3) laboratories, which showed that antipsy-
chotic potency was correlated with dopamine D2 receptor binding. The one major ex-
ception to this correlation is clozapine, which appears to be the most effective available 
drug for treating schizophrenia symptoms. The most recent version of the resulting do-
pamine hypothesis suggests that genetic, environmental, and developmental variables 
play major etiological roles in schizophrenia, but that striatal dopamine presynaptic 
overactivity remains the final trigger resulting in psychosis.
The severity and chronicity of schizophrenia have fueled efforts to identify individu-
als at risk for schizophrenia, with the assumption that a variety of psychosocial and 
medical treatments can mitigate the longitudinal course (3). Criteria for high-risk indi-
viduals and early intervention programs have been developed, and a discussion about 
including psychosis risk syndrome in DSM-5 (4, 5) has generated a lively debate. The 
basis of this debate is that many early intervention programs advocate the use of anti-
psychotic medications along with psychosocial support. The risk of metabolic side ef-
fects in high-risk individuals who do not go on to develop 
the full disorder violates the basic principle of medical 
treatment, “First, do no harm.” A Cochrane Review (6) of 
the treatment of high-risk individuals finds insufficient 
evidence of benefit thus far and suggests further study.
The article by Howes et al. (7) in this issue of the Journal 
details a prospective study involving a group of 30 subjects 
with prodromal symptoms who fall into an ultra-high-risk 
category for developing schizophrenia. These patients 
lacked only active psychotic symptoms to qualify for a 
diagnosis of schizophrenia and to become regular candi-
dates for antipsychotic medication. Using [18F]DOPA in a 
positron emission tomography study, the authors were able to show that on average, 
the patients with the highest levels of dopamine in the associative area of the striatum 
were those who converted to active schizophrenia. Increased dopamine synthesis is 
seen only in those who convert to expressing psychotic symptoms, thus qualifying for a 
diagnosis of schizophrenia. First, this finding adds to the evidence that dopamine over-
activity is the central factor driving the full manifestation of psychosis. This may not be 
specific for schizophrenia, since one of the six patients who converted to schizophrenia 
in the Howes et al. study went on to develop a bipolar illness, but it held for all five of 
those who converted to active schizophrenia. Second, it raises the question: Can such a 
screen be used to more safely start treating prodromal patients with antipsychotic drugs 
by identifying those who would convert and treating them selectively?
These data strongly support the hypothesis that dopamine overactivity, specifically in 
the striatum, is strongly associated with the emergence of psychotic symptoms and that 
overactive dopamine release in the striatum is the proximal cause of psychotic symp-
toms. This provides the strongest evidence to date that dopamine overactivity is essen-
tial for psychosis; however, the data still leave some questions unanswered. The most 
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pressing is the role of dopamine in schizotypal individuals, who as a group showed do-
pamine levels as high as those who converted to full psychosis without a single conver-
sion to a psychotic state.
The research on ultra-high-risk cohorts, which includes many studies featuring sig-
nificant psychosocial or cognitive-behavioral treatment, indicates that between 15% 
and 40% of individuals convert to schizophrenia (8). Over the past 15 years, a growing 
effort has gone into attempting to refine the ultra-high-risk diagnosis and prevent the 
onset of schizophrenia in groups with high-risk symptoms (8). Nonetheless, a recent 
article by Addington et al. (9) in the Journal showed that over 2 years, patients who did 
not convert actually improved slightly without medication. These results suggest that 
the diagnostic validity of the ultra-high-risk syndrome is not precise enough to begin 
treatment with drugs that show significant metabolic side effects; in many people, drug 
treatment may not be necessary. What is needed is a marker that identifies people who 
will convert to full psychosis and in whom treatment can be expected to prevent the de-
velopment of schizophrenia. The Howes et al. study, perhaps combined with anatomi-
cal regression data or EEG spectral power studies (10, 11), may present us with a reliable 
test battery for predicting conversion to active schizophrenia.
This marker needs to be verified; the methodological problems with schizotypal per-
sonality disorders need further follow-up; and the cost-benefit analysis of testing (using 
multiple test modalities) and treating these patients needs to be assessed before final 
diagnosis and treatment recommendations are formulated. However, we now have a 
tool that, although costly and limited in its availability, appears to be able, with consid-
erable accuracy, to identify those patients who will convert to full psychosis. This study 
will require replication and a detailed cost-benefit analysis before the recommendation 
can be made to examine patients who present with ultra-high-risk symptoms; however, 
it provides a potential vehicle for getting treatment to those who will benefit and pro-
tecting those who will not from a potentially harmful course of treatment.
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